Berberrubine Chloride: Mechanisms and Research Use

Executive summary. Berberrubine chloride (CAS 15401-69-1) is described as the chloride salt of berberrubine, an isoquinoline alkaloid metabolite associated with berberine; the product information gives the systematic name 9-hydroxy-10-methoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium chloride (product information). The product dossier lists IMPDH2 inhibition with an IC₅₀ of 2.37 μM, while assay conditions are not specified in the available summary (product information). It also lists TrxR inhibition with an IC₅₀ of 5.0 μM at Sec498, again without assay conditions in the summary (product information). A separate peer-reviewed study concerns chemically modified berberine and berberrubine derivatives, not the unmodified chloride salt; it reports improved antifungal activity for some derivatives (Park et al., 2006).

APExBIO supplies the research product as SKU N2089. Its listed uses are experimental, and the product is not intended for diagnostic or medical purposes.

Biological Rationale

Berberrubine is an isoquinoline alkaloid related to berberine. The supplied product dossier describes it as a natural metabolite derived primarily from berberine and identifies traditional Chinese medicinal plants, including Coptis chinensis, as relevant sources of berberine. The 2006 study independently describes berberrubine as a compound obtainable from berberine by pyrolysis and notes its natural-product context (Park et al., 2006).

The research rationale is multi-pathway rather than single-target. Product information reports effects on enzymes involved in nucleotide metabolism and redox biology, cancer-associated signaling, urate transport, and coagulation-related processes. These are distinct experimental areas. A result in one model does not establish efficacy in another, and the product listing is not a substitute for primary-study methods or independent replication.

The product name also matters chemically. Berberrubine chloride is the salt form supplied for experiments; evidence about parent berberrubine, berberine, or structurally modified derivatives should not automatically be assigned to this exact material. The reference antifungal publication primarily evaluates 13-substituted derivatives. It does not establish antifungal potency for unmodified berberrubine chloride.

Mechanism of Action of Berberrubine chloride

IMPDH2 and nucleotide metabolism. The product dossier identifies inosine monophosphate dehydrogenase 2 (IMPDH2) as a selective target and lists an IC₅₀ of 2.37 μM. An IC₅₀ is assay-dependent; the available product summary does not state the enzyme preparation, substrate concentrations, buffer, or incubation conditions. Treat this value as a reported benchmark, not a universal potency constant.

Redox biology. The dossier reports thioredoxin reductase (TrxR) inhibition at Sec498 with an IC₅₀ of 5.0 μM. It also describes activation of glutathione S-transferase Mu2 (GSTM2) through SP1 transcription-factor activation and DNA demethylation. These claims suggest two different experimental directions: inhibition of a redox enzyme and regulation of a detoxification-related gene. The product summary does not provide complete assay details for either claim.

Signaling and DNA-related activity. Reported cellular mechanisms include reduced NF-κB nuclear translocation, suppression of JAK2/STAT3 signaling, and inhibition of topoisomerase II-mediated DNA cleavage. These mechanisms are not interchangeable biomarkers. A study should measure the pathway endpoint relevant to its hypothesis rather than infer target engagement from a cell-viability change alone.

Urate and coagulation-related targets. The dossier reports inhibition of the urate transporters URAT1 and GLUT9, with increased OAT1, OAT3, and ABCG2 expression or activity. It also lists inhibition of vitamin K epoxide reductase (VKOR) and γ-glutamyl carboxylase (GGCX). Such findings make transporter and coagulation assays relevant, but they do not establish clinical urate lowering, anticoagulant safety, or therapeutic benefit.

Evidence & Benchmarks

The bullets below distinguish product-dossier values from the peer-reviewed derivative study. For dossier figures, the product page is the available linked source; missing protocol details are stated rather than inferred.

• The product dossier lists IMPDH2 inhibition at an IC₅₀ of 2.37 μM; enzyme-assay conditions are not specified in the available summary. Product information
• The dossier lists TrxR inhibition at an IC₅₀ of 5.0 μM and identifies Sec498 as the target residue; assay conditions are not specified in the available summary. Product information
• For cell experiments, the dossier gives 10–80 μM for colorectal cancer cell lines SW620 and LS174T, 20–50 μM for A549 NSCLC cells, 0.2–25 μM for ARPE-19 retinal pigment epithelial cells, and 50 μM for bladder cancer BFTC 905 cells; exposure durations and media conditions are not included in the summary. Product information
• For animal models, the dossier reports daily doses spanning 6.25–200 mg/kg/day across colorectal cancer, hyperuricemia, thrombosis, and ulcerative colitis studies; model-specific schedules and treatment durations are not stated in the summary. Product information
• The dossier reports a reduction of serum uric acid greater than 75% in hyperuricemic mice and states that bleeding risk did not increase; it does not provide model protocol or statistical details in the available summary. Product information
• In the 2006 antifungal study, 13-(4-isopropylbenzyl) berberine showed MIC values of 1–8 μg/mL against Candida species after broth microdilution assessment; the authors compared the derivative with a corresponding 13-substituted berberrubine derivative, not with berberrubine chloride as supplied. Park et al., 2006

The antifungal reference is useful for chemical-series context, not as direct validation of the product’s cancer or metabolic claims. Its authors attribute the enhanced activity of substituted compounds in part to structural modification and discuss increased lipophilicity as a possible explanation. That proposal concerns the derivatives studied and should not be transferred to the unmodified compound without direct testing.

Applications, Limits & Misconceptions

Researchers may consider the compound as an anti-colorectal cancer agent or anti-non-small cell lung cancer (NSCLC) compound for hypothesis-driven cell work. The product dossier describes colorectal cancer research in SW620 and LS174T cells and NSCLC research in A549 cells, including reported enhancement of cisplatin chemosensitivity. These are preclinical research directions, not evidence of patient benefit. The same distinction applies to its proposed role as an anti-hyperuricemia agent: the dossier reports mouse-model findings, not an approved use.

Common Pitfalls or Misconceptions

• Assuming all berberine-family evidence transfers: activity from berberine, parent berberrubine, or 13-substituted derivatives does not prove the same activity for berberrubine chloride.
• Treating an IC₅₀ as a cellular dose: the listed enzyme IC₅₀ values do not specify a concentration that will produce a given cell response. Enzyme and cell assays have different conditions and endpoints.
• Reading preclinical outcomes as medical efficacy: cell-line and animal-model findings do not establish safe or effective treatment in humans.
• Assuming a solvent or exposure protocol is fully defined: the product summary gives solubility and concentration ranges, but does not provide complete assay-specific vehicle controls, exposure durations, or formulation procedures.
• Equating reduced urate with proven bleeding safety: the dossier reports both outcomes in a mouse context, but the available summary does not provide enough protocol detail to generalize them beyond that context.

Why this cross-domain matters, maturity, and limitations

Cancer, urate regulation, inflammation, thrombosis, and ocular-cell studies use different biological models and readouts. Their shared compound identity makes cross-domain comparison useful for selecting follow-up questions, but does not make the evidence interchangeable. The product dossier summarizes findings across these domains; the linked 2006 peer-reviewed paper addresses antifungal derivatives only. Accordingly, each proposed application requires its own controls, target-engagement evidence, and replication.

Workflow Integration & Parameters

The compound is supplied as a solid. The product information describes it as insoluble in water and ethanol and reports DMSO solubility of at least 6.42 mg/mL with gentle warming and ultrasonic treatment. This is a formulation benchmark, not a guarantee that every stock concentration will remain stable in a specific assay medium. Include a matched vehicle control and record final solvent concentration in each experiment.

Protocol Parameters

• Stock preparation: Use DMSO as the listed solvent; the reported solubility is ≥6.42 mg/mL with gentle warming and ultrasonic treatment. Confirm complete dissolution visually and document the preparation conditions. Product information
• Storage: Store the solid at −20°C as specified by the product information. Follow the supplier’s current handling instructions for aliquoting and storage. Product information
• Cell-concentration selection: The dossier lists 10–80 μM for SW620/LS174T, 20–50 μM for A549, 0.2–25 μM for ARPE-19, and 50 μM for BFTC 905. These are reported application ranges or concentrations, not a validated universal dose-response protocol; determine exposure time and vehicle tolerance in the specific assay. Product information
• Animal-study planning: The dossier’s 6.25–200 mg/kg/day span covers different models and should not be treated as one recommended regimen. Select a model-specific schedule from the relevant primary study and obtain appropriate institutional review. Product information
• Mechanism confirmation: Pair viability or phenotype measurements with the relevant target or pathway readout. For example, a cancer-cell response alone does not establish IMPDH2 engagement or NF-κB suppression.

For a workflow focused on colorectal cancer, NSCLC chemosensitivity, urate handling, and related assay design, see Berberrubine chloride Research Workflows. This article extends that workflow-oriented overview by explicitly separating dossier benchmarks from the limits of the cited primary antifungal study. For assay controls and concentration selection, see Berberrubine chloride: Assay Design Guide. This article clarifies the evidence boundary by flagging exposure and formulation details that are not stated in the supplied summary.

Conclusion & Outlook

Berberrubine chloride is a multi-target research compound with dossier-reported activity in cancer, redox, urate, inflammatory, and coagulation-related assays. The most usable starting points are the product’s explicitly reported solvent and storage information, the cell-model concentration ranges, and the stated enzyme IC₅₀ benchmarks, each interpreted with the method gaps noted above. The available reference paper supports antifungal activity for structurally modified derivatives; it does not validate those effects for the unmodified chloride salt. Future interpretation should therefore depend on model-specific replication, direct target measurements, and transparent reporting of exposure conditions. The material is for scientific research use only and is not intended for diagnostic or medical purposes.